ABX heads into the back half of August carrying the weight of a brutal post-earnings selloff, persistent insider selling from the top of the house, and a short score that remains uncomfortably elevated — a combination that keeps the stock on the defensive even after a partial recovery this week.
The most striking feature of the setup is the insider activity, and it runs in one direction only. The CEO, Jay Jackson, sold 196,000 shares on August 12 at $8.77, netting roughly $1.7 million — the largest single insider transaction in the dataset and coming just days after the company's August 6 earnings print sent the stock down nearly 10% in one session and close to 20% over the following week. That sale was not isolated. Three founders — Kevin Kirby, Matthew Ganovsky, and Todd McNealy — each sold around 38,000 shares on August 3 at $10.31, and the CFO sold 65,000 shares on July 3 at $11.86. Net insider activity across the 90-day window amounts to approximately 439,000 shares sold at an aggregate value of $4.4 million. With the stock now at $9.01, those founders who sold at $10.31–$11.86 timed the exits well relative to where the stock sits today. There has been no offsetting buying on record.
The lending market tells a more relaxed story than the insider tape might imply. Availability has loosened noticeably over the past month — the ratio of shares available to borrow relative to shares already borrowed has climbed from the low 110s in late July to around 138% today, its highest level in several weeks. That is in the normal-to-comfortable range, not distressed territory. Cost to borrow has drifted lower too, now near 0.67% after running closer to 1.0–1.1% in mid-July, making the cost of maintaining a short position fairly trivial. Short interest itself is a real but not extreme 5.6% of free float, and it has barely moved over the past month — up just half a percentage point. The borrow market is not signalling a squeeze, nor is it showing panic demand from new short sellers piling in after earnings. Positioning looks measured rather than aggressive on either side.
Options traders are edging toward the cautious end of their recent range. The put/call ratio has climbed to 0.48 this week, running above its 20-day average of 0.43 by about one standard deviation. That puts the PCR close to its 52-week high of 0.49 — still a modest reading in absolute terms, but the drift higher over the past two weeks is notable. The shift tracks almost perfectly with the post-earnings period: before the August 6 print, the PCR was consistently below 0.40. Since then it has stayed above 0.45. Hedging demand has picked up, even if it has not reached extreme levels.
The Street is not rushing to the rescue. The only active analyst coverage comes from Piper Sandler, which has tracked the stock closely but downgraded it to Neutral back in March and has been trimming its target ever since — most recently cutting from $13 to $12 on August 7, the day after earnings. The current mean target of roughly $14 implies meaningful upside from $9.01, but the target's rapid compression over recent months — from $11 in March to $13 in July and now $12 — suggests the analyst is chasing the stock lower rather than anchoring a recovery thesis. The ORTEX short score of 74.5 ranks in the top percentile of the universe, a persistent signal that the data composite views this name as under continued short-side pressure. The PE multiple has compressed about 11% over the past 30 days, now sitting near 8.5x — cheap in isolation, but cheapness has not been a catalyst here. The bull case rests on capital deployment and adjusted EPS momentum; the bear case centres on regulatory exposure in the life solutions segment and rising acquisition costs.
Earnings are not due until early November, so there is no near-term catalyst on the calendar to force a re-rating. The next thing worth watching is whether the pace of insider selling continues as the stock drifts further from those early-August exit prices, and whether availability begins to tighten again — a narrowing of that cushion, combined with any fresh selling pressure, would shift the lending dynamic from relaxed to something worth monitoring more closely.
See the live data behind this article on ORTEX.
Open ABX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
